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Abstract
Background: CD90+ liver cancer cells have been described as cancer stem-cell-like (CSC), displaying aggressive and
metastatic phenotype. Using two different in vitro models, already described as CD90+ liver cancer stem cells, our
aim was to study their interaction with endothelial cells mediated by the release of exosomes.
Methods: Exosomes were isolated and characterized from both liver CD90+ cells and hepatoma cell lines.
Endothelial cells were treated with exosomes, as well as transfected with a plasmid containing the full length
sequence of the long non-coding RNA (lncRNA) H19. Molecular and functional analyses were done to characterize
the endothelial phenotype after treatments.
Results: Exosomes released by CD90+ cancer cells, but not by parental hepatoma cells, modulated endothelial
cells, promoting angiogenic phenotype and cell-to-cell adhesion. LncRNA profiling revealed that CD90+ cells were
enriched in lncRNA H19, and released this through exosomes. Experiments of gain and loss of function of H19
showed that this LncRNA plays an important role in the exosome-mediated phenotype of endothelial cells.
Conclusions: Our data indicate a new exosome-mediated mechanism by which CSC-like CD90+ cells could
influence their tumor microenvironment by promoting angiogenesis. Moreover, we suggest the lncRNA H19 as a
putative therapeutic target in hepatocellular carcinoma.
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Background
Hepatocellular carcinoma (HCC) is the third leading cause
of cancer mortality worldwide [1]. Primary HCC lesions
can be removed completely when detected at an early
stage, but intrahepatic recurrence of HCC and extrahe-
patic metastasis are very frequent, giving rise to a poor
prognosis for patients [2, 3]. It is widely accepted that both
differentiated hepatocytes and cells with progenitor char-
acteristics, known as cancer stem cells (CSCs), can cause
HCC [4–7]. Forty percent of HCCs are clonal, and poten-
tially derived from progenitor/stem cells. Moreover, these
cells have a critical role in the development and progres-
sion of HCC [8]. Liver CSCs have been isolated from pri-
mary HCC specimens and patients’ sera as circulating
cells, and from HCC cell lines by use of surface antigens
[9–11]. CD90, the epithelial cell adhesion molecule
(EpCAM) and CD133 have been found to recognize
three distinct cell populations that differ from one an-
other in features and behavior in determining cancer
phenotypes [12].
CD90 (Thy-1) is a 25-37 kDa glycophosphatidylinosi-
tol (GPI)-anchored protein expressed by several cells
such as T-cells, neurons, endothelial cells and fibro-
blasts. It is involved in cell-to-cell and cell-matrix inter-
action, apoptosis, adhesion, migration, fibrosis, and
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cancer development [13]. Concerning the liver, the ex-
pression of CD90 has been linked to hepatic stem/pro-
genitor cells [14] and, during tumor growth, it has been
correlated with an aggressive phenotype [15], and associ-
ated with low differentiated HCC and poor prognosis
[16–18]. CD90+ CSCs obtained from HCC cell lines,
from tumor tissues and peripheral blood as circulating
cancer cells displayed, in contrast to the other CSC pop-
ulations, a mesenchymal phenotype and, most import-
antly, a greater capacity to metastasize when injected into
immunodeficient mice [11, 12, 19]. Moreover, recent data
associate CD90 expression with early HCC recurrence [20].
Gene expression and miRNA analysis in CD90+ HepG2
cells have revealed an imbalance in the expression of apop-
totic and anti-apoptotic genes compared with CD90 nega-
tive cells [21]. However, we are still far from understanding
the molecular mechanisms underlying the more aggressive
and metastatic phenotype of these cells compared with the
other liver cancer cells.
Tumor development is dependent on the reciprocal in-
teractions between cancer cells and the surrounding
microenvironment. It is well known that in addition to
pathways involving cell-to-cell contact and the release of
soluble factors, cancer cells are able to communicate with
the tumor microenvironment (e.g., myeloid cells, fibro-
blasts, endothelial cells) through the intercellular exchange
of proteins and genetic materials via exosomes [22].
Exosomes are spherical membrane vesicles of endocy-
tic origin, with an average size of 40 to 150 nm [23], re-
leased by both normal and diseased cells after the fusion
of multivesicular bodies with the plasma membrane.
First considered as collectors of cellular waste materials,
exosomes have assumed a leading role in the regulation
of the tumor microenvironment. Depending on their
content, exosomes can affect tumor cells and surround-
ing stroma by influencing major cellular pathways, such
as apoptosis, cell differentiation, angiogenesis, and me-
tastasis [24]. These vesicles act as cargos that release
bioactive molecules e.g., lipids, proteins, and nucleic
acids in target cells. Interestingly, recent observations
have identified a vesicle–mediated transfer of lncRNAs
as an important mechanism in the development of HCC
[25]. In this paper we demonstrate that CD90+ cells, de-
rived from HCC cell lines, release exosomes that, in
turn, are able to influence endothelial cells by promoting
angiogenesis and stimulating their adhesive properties.
Furthermore, our results suggest the lncRNA H19 as a
possible mediator of angiogenic effects.
Results
CD90+ cells show a mesenchymal phenotype and actively
release exosomes
As reported by Yang and colleagues [11], highly positive
CSC-like CD90+ cells were isolated by cell sorting,
starting from Huh7 cell line presenting a mean of 4 %
CD90+ cells and 2 % CD90 high-expressing cells. After
sorting, the purity of the selected CD90+ population was
monitored during cell passages by FACS analysis, and
the cells were kept in culture until they maintained a
positivity for CD90 of over 90 % (at approximately the
40th passage). Isolated CD90+ cells, in contrast to the
parental Huh7 and as already described by others [12],
showed a mesenchymal phenotype, revealing a deloca-
lized E-Cadherin and a lack of expression of HNF4α, a
master regulator of hepatocytic differentiation (Fig. 1a).
On the contrary, most of the cells were positive for
vimentin, a component of intermediate filaments in
mesenchymal cells (Fig. 1a). In order to evaluate the
ability of Huh7 and its CD90+ subpopulation to release
nanovesicles, the conditioned medium was collected,
and the vesicles isolated as described by members of our
group [26, 27]. Measures obtained by DLS revealed, in the
ultracentrifuged cell culture medium, vesicles with an
average size in diameter of 50 nm and 100 nm from CD90
+ or Huh7 cell medium, respectively (Fig. 1b). This in line
with the exosomes dimensions between 30 and 150 nm
[28]. Moreover, Western blot analyses showed that Alix
and Tsg101 markers are expressed but not enriched in
exosomes released by CD90 +Huh7 (Fig. 1c).
Exosomes released by CD90+Huh7 cells affect HUVECs by
promoting tube formation and cell-cell adhesion
CD90 +CSCs have been associated with metastasis and
early recurrence in HCC [12, 20]. In order to evaluate
whether the CD90+Huh7 cells were able to influence the
tumor microenvironment, we treated HUVECs with exo-
somes released by CD90+ Huh7 cells or Huh7 parental
cells (CD90 + exo and Huh7exo). Endothelial cells rapidly
internalized exosomes from both cell types; uptake was
evident after one-hour of incubation at 37 °C, and in-
creased over the course of six hours (Fig. 1d). Eighteen
hours after exosome treatment, real-time PCR analysis re-
vealed that the addition of CD90 + exo, but not of
Huh7exo, highly increased the mRNA levels of the pro-
angiogenic factor VEGF and its receptor VEGF-R1 in
endothelial cells (Fig. 2a). ELISA assay showed that
HUVECs treated with CD90 + exo released three-fold
more VEGF (Fig. 2b, left panel). Moreover, a significant in-
crease in the number and the length of tubular-like struc-
tures was observed when HUVECs were treated with
CD90 + exo compared with Huh7exo (Fig. 2b, middle and
right panels).
Liver CD90+ CSCs were found circulating in HCC pa-
tients and in metastatic colonies [19]. For this reason,
we tested the ability of exosomes released by the hepa-
toma cell line or by sorted CD90+ cells to modulate the
adhesion to an endothelial cell monolayer, a crucial
event for intra- or extra-vasation. As revealed by real-
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time PCR (Fig. 2a), and confirmed by FACS analysis
(Fig. 2c), treatment of HUVECs with CD90 + -derived
exosomes modulated intercellular adhesion molecules,
inducing an increase in the expression of ICAM-1.
No significant differences were found in VCAM and
VE-Cadherin gene expression (data not shown). To
validate our data, we did an adhesion assay, pre-
treating endothelial cells with exosomes. As shown in
Fig. 2d, CD90 + exo caused a two-fold increase in ad-
hering cells compared with pre-treatment Huh7 exo.
To further confirm our observation, the same experi-
ments were performed with SkHep, a hepatoma cell line
Fig. 1 CD90+ population. a Huh7 and sorted CD90+ Huh7 were stained for hepatocytic (HNF4alpha), epithelial (E-Cadherin) and mesenchymal
(Vimentin) markers, in blue the nuclear staining with DAPI. Characterization of isolated exosomes. b Dynamic light scattering of vesicles isolated from
Huh7 (in black) and from CD90 +Huh7 cells (in red). c Western blot for endosomal markers Alix, Tsg101 and HSC70 in Huh7 and CD90+Huh7
population with their relative exosomes. d Confocal microscopy analysis on HUVECs treated for 1, 3, and 6 h with 5 μg/ml of exosomes from
CD90+ or Huh7 cells. HUVECs were stained with phalloidin Alexa Fluor488 (green), nuclear counterstaining was done using DAPI (blue),
exosomes were labelled with PKH26 (red)
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already characterized as 100 % CD90+, and displaying
mesenchymal stem cell characteristics [29]. Additional
file 1 illustrates the characterization of exosomes re-
leased by SkHep and their uptake by HUVECs, that
present different features compared to CD90+ Huh7
derived exosomes. In addition, measures obtained by
DLS revealed, in the ultracentrifuged SKHep culture
medium, exosomes with an average size in diameter of
70 nm expressing high level of the exosomal markers
TSG101 and HSC70. As observed for CD90 + exo, the
SkHep-derived exosomes induced a pro-angiogenic
stimulus in endothelial cells, modifying their transcrip-
tional profile and enhancing tube formation in matrigel,
as well as increasing the adhesive properties of
HUVECs.
In summary, our results showed that exosomes re-
leased by CSC-like CD90+ liver cells, but not from hepa-
toma cells, induce pro-angiogenic stimuli in HUVECs,
Fig. 2 HUVECs characterization after exosomes treatment: a RT-PCR analyses for VEGF, VEGF-R and ICAM1 were done on HUVECs 18 h after
treatment with CD90+ or Huh7-derived exosomes (5 μg/ml). ΔΔct expressed as fold of induction (FOI) compared with control (untreated cells).
***p < 0.001; *p < 0.05. b Left panel: ELISA for VEGF released by HUVECs 18 h after treatment with CD90 + exo or Huh7exo. Untreated cells were used as
control. *p< 0.05. Middle-right panels: Tubulogenesis analysis. Phase contrast micrographs (20×) and quantification of matrigel assay expressed as length
of cable as arbitrary unit. c FACS analysis for ICAM-1 on HUVECs 18 h after treatment with Huh7exo or CD90 + exo, respectively. d Adhesion capacity. Left
panel: Phase contrast micrographs (20×) showing the adhesion of CD90 + cells on HUVEC monolayer pre-treated with Huh7exo or CD90 + exo. Right
panel: Quantification of adhesion established by counting the number of adherent CD90 + cells (violet) per field; *p< 0.05
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and influence the adhesion between CD90+ cells and
endothelial cells.
CD90+ cells express the lncRNA H19 and release it via
exosomes
It has been confirmed that dysregulation of lncRNAs is
associated with several human tumors and, recently, a
contribution of lncRNAs to hepatocarcinogenesis was
found [30–32]. In order to clarify the molecular mechan-
ism driving the modifications induced in HUVECs by
CD90 + -derived exosomes we did an lncRNA profile study
in CD90+ cells and parental Huh7 by analyzing the expres-
sion of 90 different lncRNAs. In Fig. 3a (left and middle
panel), the RNAs over-expressed in CD90+Huh7 cells
compared with Huh7 parental cells with at least a ten-fold
increase are listed. Among these, Air, Hotair, LincRNA-
ROR, Hulc, and H19 have already been identified as posi-
tively correlated with hepatocellular carcinoma [31, 33, 34].
We focused our interest on H19, expression of which has
been previously associated with metastasis [35, 36]. In line
with recent articles, which have demonstrated that hepato-
cellular carcinoma cells release exosomes containing
lncRNA [25, 37], we investigated the expression in exo-
somes, of those LncRNAs that we found overexpressed in
cells. As shown in Fig. 3a right panel the LncProfiler per-
formed on CD90+ Huh7 and Huh7-derived exosomes
evidences that H19 was 10-fold up-regulated in exosomes
derived from CD90+ Huh7, compared to parental cell line.
The Real-time PCR confirmed that vesicles released by
CD90 + cells (both sorted or SkHep cells) are highly
Fig. 3 a. LncRNAs expressed in CD90+ cells and their exosomes (left and middle panel). Data are expressed as fold induction compared with
Huh7 mix population. Of the 90 lncRNAs analyzed, only those over-expressed more than ten-fold in CD90+ cells were considered. Listed on the
right the lncRNA up-regulated in HCC. Right panel: LncRNA Profile in exosomes released by CD90 + Huh7. Data are expressed as fold of induction
compared with exosomes from Huh7 parental cells. b H19 analysis. Real-time PCR analysis for H19 expression in exosomes derived from Huh7 or
CD90+ cells. Exosomes were treated with RNase and subsequently processed for RNA extraction and retrotrascription. Data were normalized for
β-actin and ΔΔct indicated as fold of induction compared with Huh7-derived exosomes. ***p < 0.001. c Real-time PCR for H19 on HUVEC 18 h
after treatment with CD90 + exo or Huh7exo. Data were normalized for β-actin and ΔΔct indicated as fold of induction compared with control
(untreated cells). ***p < 0.001
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enriched in H19 transcript compared with vesicles from
Huh7 parental cells (Fig. 3b, S1e). Moreover, treatment
with CD90 + -derived exosomes induced in HUVECs an
increase in H19 transcript (Fig. 3c, S1f). These data sug-
gest a transport of H19 lncRNA from CD90+ cells to
HUVECs, even if we cannot exclude a stimulation of en-
dogenous lncRNA.
LncRNA H19 stimulates angiogenesis and promotes the
adhesion of CD90+Huh7 cells to endothelial cell
monolayer
To investigate a possible role of H19 as mediator of pro-
angiogenic and adhesive stimuli in HUVECs, we trans-
fected endothelial cells with the entire sequence of the
lncRNA H19 (pH19). As shown in Fig. 4a, H19 overex-
pression in HUVECs induced a transcriptional modula-
tion similar to that obtained after CD90 + exo treatment.
Real-time PCR indicated that the over expression of H19
induced a significant increase in the VEGF and ICAM1
transcripts, while, no modulation compared to controls
was observed for the transcription of VEGF-R1, VCAM
and VE-cadherin (Fig. 4a right panel). The ELISA assay
(Fig. 4a left panel) found, for the first time to our know-
ledge, a substantial increase in VEGF release induced by
lncH19. Moreover, a rise in the number and length of
tubes was found in HUVECs transfected with pH19
(Fig. 4b), while FACS analysis (Fig. 4c) indicated an
increase in the number of ICAM-1-expressing cells
induced by H19 overexpression, thus explaining the
more adhesive phenotype of HUVECs. The adhesion
assay, in fact, revealed a two-fold increase in adhering
CD90+ cells when HUVECs were transfected with
pH19 (Fig. 4d).
Overall, these data demonstrate, for the first time to
our knowledge, the ability of the lncRNA H19 to stimu-
late angiogenesis, and to favor cell-cell interaction,
allowing us to postulate H19 as a possible mediator of
pro-metastatic properties of exosomes released by
CD90+ cells. To confirm our hypothesis, lncH19 was si-
lenced in HUVECs concomitantly with CD90 + exo
treatment. As shown in Fig. 5a, the silencing of H19 ab-
rogated the exosome-mediated induction of VEGFR1,
while no modulation was revealed in the expression of
ICAM1. Concerning the VEGF, even if the reduction of
transcript did not appear significant (5a), the release of
VEGF protein induced by exosome treatment was to-
tally inhibited by H19 silencing (5b).
Discussion
CD90+ liver CSCs have been found in primary tu-
mors, and circulating in the blood of HCC patients,
and are associated with early recurrence, metastasis,
and poor prognosis [19, 20]. Our study highlights the
ability of CSC-like CD90+ cells, but not hepatoma
cells, to influence endothelial cell phenotype through
the release of exosomes.
In a solid tumor, the CSC’s niche is composed of an
extracellular matrix (ECM), mesenchymal stem cells,
tumoral cells, immune cells, and endothelial cells, all of
which converge in determining the fate of CSCs
through extracellular signals [38]. Little is known about
the modulation of the tumor microenvironment by
CSCs. Several studies have described exosomes as sig-
naling extracellular organelles that modulate the tumor
microenvironment, promoting angiogenesis and tumor
progression [27, 39]. Our data indicate that exosomes
released by CSC-like CD90+ liver cells are able to
promote an angiogenic phenotype in cultured endo-
thelial cells. CD90 + -derived exosomes induced in
HUVECs an increase in the production and secretion
of VEGF, the most powerful pro-angiogenic cytokine,
as well as of its receptor VEGF-R1. This increase was
accompanied by an amplification in the number and
length of tube-like structures formed by HUVECs in
culture.
It is abundantly documented that metastatic processes
induce changes in the endothelial surface antigens, with
an increase in adhesion molecules, which, in turn, favor
the adhesion and the consequent intra- or extra-vasation
of metastatic cells. We found that exosomes released by
CD90+Huh7 cells, and not by hepatoma cells, increased
the number of HUVECs expressing ICAM-1 and, more
extensively, increased the adhesion between endothelial
cells and the CSC-like CD90+ cells. Our data also indi-
cate that the CD90+ released exosomes may be able to
promote metastasis.
Recently, Patel et al. demonstrated that lncRNA could
be selectively packaged in extracellular vesicles released
by hepatoma cell lines and transported to other cells,
with subsequent modulation of cellular function [25,
40]. LncRNA are emerging as molecular players in sev-
eral biological processes acting at epigenetic, transcrip-
tional and post-transcriptional levels or processing
small non-coding RNAs [41]. H19 was among the first
lncRNAs to be identified and studied principally for its
monallelic expression, and as regulator of IGF2 abun-
dance [42, 43]. As already described for other
lncRNAs, H19 can work as a microRNA sponge, miR-
NAs precursor, or epigenetic modulator [44, 45], and
has been found overexpressed in several tumors, and
able to promote tumor growth [46, 47] and progres-
sion [47, 35, 36]. Concerning the liver, H19 has been
clearly involved in hepatocarcinogenesis [48] and hep-
atic metastases [49]. Several indications correlate H19
with angiogenesis [50, 51]. Northern analysis has indi-
cated a high expression of H19 during development of rat
aorta that decreases in differentiated tissue and, interest-
ingly, re-appears following vascular injury in vivo and in
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Fig. 4 H19 overexpression. a Left panel: Real-time PCR performed on HUVECs 18 h post-transfection. Data were normalized for β-actin and ΔΔct
expressed as fold of induction pH19 vs. pEmpty **p < 0.01; *p < 0.05. Right panel: ELISA assay for VEGF level in supernatant from HUVECs 18 h after
transfection. ***p < 0.001. b Left Panel: Phase contrast (20×) of tubulogenesis assay performed 18 h after transfection. Right panel: quantification
of matrigel assay expressed as length of cable as arbitrary unit*p<0.05. c FACS analysis for ICAM expression in HUVEC transfected cells. d Left
Panel: Phase contrast micrographs (20×) showing the adhesion of CD90 + cells on HUVEC monolayer transfected with pEmpty or pH19. Right
Panel Quantification was calculated by counting the number of adherent CD90+ cells (violet) per field. **p < 0.01
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vitro [50], though no observations of the overexpression
of H19 in endothelial cells have been published.
In this study, we demonstrate, for the first time to our
knowledge, that H19 is highly expressed in a subpopula-
tion of hepatoma cells that expose the surface antigen
CD90 and are characterized, by others, as CSC-like cells
[11, 12, 15, 29]. We found that CD90+Huh7 cells pack-
age lncRNA H19 inside exosomes, thus delivering it to
possible target cells. Exosomes released by CD90+ liver
cancer cells could be internalized by endothelial cells, in-
fluencing these in a pro-metastatic way. Moreover, we
identified in H19 an important player of this process.
H19 overexpression in endothelial cells is able to up-
regulate the VEGF production and release, increase the
ability of HUVEC cells to arrange in vitro tubular-like
structures, and promote heterotypic adhesion between
endothelial cells and CSC-like liver cells. Silencing ex-
periments revealed LncRNAH19 as the principal player
of the exosome-mediated VEGF increase, while sug-
gested the presence of other molecular actors that,
transported or induced by CD90 + -derived exosomes,
and together with H19, affect endothelial cells in a pro-
metastatic way. However, the mechanisms of action
through which this lncRNA controls an endothelial
phenotype remain to be elucidated.
Conclusion
Our in vitro experiments demonstrated that CD90+ liver
cancer cells release exosomes that, in turn, are able to
affect endothelial cells in a pro-metastatic way. Exo-
somes derived by CD90+Huh7 cells and H19 may repre-
sent two new therapeutic targets for reducing recurrence
and metastasis of HCC.
Material and methods
Cell culture and reagents
Human umbilical vein endothelial cells (HUVECs) were
obtained from Lonza (Verviers, Belgium) and grown in
endothelial growth medium (EGM, bullet kit, Lonza) ac-
cording to supplier’s instructions. Huh7 cells and Sk-
Hep cells were cultured in DMEM medium (Euroclone,
UK), and supplemented with 10 % fetal bovine serum
(Euroclone, UK), 2 mM L-glutamine, 100 U/ml penicil-
lin and 100 mg/ml streptomycin (Euroclone, UK).
Sorting CD90+Huh7 cells
Huh-7 human hepatocellular carcinoma cells were
stained with anti-CD90 PE (BD Pharmingen™ 555596),
and surface marker was determined by flow cytometry.
CD90+ and CD90- cells were sorted through a FAC-
SAria I (BD Biosciences). A purity check was done after
the sorting by re-running a small fraction of the sorted
populations. All cells showed over 85 % purity.
Immunocytochemistry
Immunocytochemistry was done on PFA 4 % fixed cells,
and stained with the following antibodies: the primary
antibodies were anti-E-Cadherin (BD Biosciences
610181), anti-HNF4a (Abcam ab41898), and anti-
Vimentin (Epitomics, 2707-1); the secondary antibodies
were Alexa-Fluor 488 and Alexa-Fluor 594, from Mo-
lecular Probes. The nuclei were stained with NucRed®
Live 647 (Catalog number: R37106, Life Technologies),
and preparations were analyzed by confocal microscopy
(Leica TSC SP8).
Fig. 5 a Real-time PCR for H19, VEGF, VEGFR1 and ICAM1 from HUVECs transfected with H19 siRNA or negative scramble and treated with CD90 +
exo. Data were normalized for β-actin and ΔΔct expressed as fold of induction siRNA H19 versus negative control. **p < 0.01, ***p < 0.001 b ELISA assay
for VEGF detection on the supernatant from HUVECs treated as indicated above. ***p < 0.001
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Exosome preparation and characterization
Huh7, CD90+ Huh7 and Sk-Hep cells were grown with
10 % ultracentrifugated FBS, and conditioned medium
was collected 48 h after culture; exosomes were subse-
quently isolated by serial centrifugation [26]. Briefly, cul-
ture medium was centrifuged subsequently for 5 min at
300 × g, 15 min at 3,000 × g, 30 min at 10,000 × g and
ultracentrifuged 90 min at 100,000 × g in a Type 70 Ti,
fixed angle rotor. Peletted exosomes were washed and
then resuspended in PBS. Exosome protein content was
determined with the Bradford assay (Pierce, Rockford,
IL, USA). On average we recovered 10 micrograms of
vesicles from 25 ml of conditioned medium from 3 × 106
cells. The intensity autocorrelation functions of diluted
vesicle samples were measured by dynamic light scatter-
ing (DLS) using a Brookhaven Instruments BI-9000 cor-
relator and a BI200-SM goniometer, equipped with a
solid-state laser tuned at 532 nm. The size distribution
was determined from the vesicle diffusion coefficients by
standard analysis [52]. Thirty μg of protein for each sam-
ple, exosomes, and cells, were analyzed by western blot
for Alix (3A9-Cell Signaling Technology #2171S),)
Tsg101 (Santa Cruz Biotechnology sc-7964) and HSC70
(Santa Cruz Biotechnology sc-7298).
Uptake of exosomes by HUVECs
Exosomes from Huh7, CD90+ Huh7 and SkHep cells
were labeled with PKH26 according to supplier’s instruc-
tions, suspended in low serum medium (5 μg/ml), and
incubated with HUVECs for 1, 3, and 6 h at 4° or 37 °C.
After incubation, cells were processed as previously
described [26].
HUVECs treatment
HUVECs were grown at a density of 100.000cells/well in a
12 wells plate, and treated for 18 h with 5 μg/ml of exo-
somes in low serum medium; untreated cells were consid-
ered control. Plasmid for psiCHECK2-H19 and the Empty
vector psiCHECK2 (kindly provided by Dr Y. Huang
[45]]), H19 siRNA (SR319206B Origene Technologies)
and scramble negative control (SR30004 Origene Tech-
nologies) were transfected in HUVECs with Attractene
Transfection Reagent (cat.number.1051531, Quiagen) fol-
lowing manufacturer’s indications.
RNA extraction and real-time PCR
RNA was extracted using the commercially available
illustra RNAspin Mini Isolation Kit (GE Healthcare), ac-
cording to manufacturer’s instructions. Total RNA was
reverse-transcribed to cDNA using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystem).
RT-QPCR was done in 48-well plates using the Step-
One Real-Time PCR system (Applied Biosystem). Real-
time PCR was performed in duplicates for each data
point. For sybr-green method the oligonucleotide used
were β-actin for5’-ATCAAGATCATTGCTCCTCCTGA-
3’rev 5’CTGCTTGCTGATCCACATCTG-3’; H19 for5’-
GCACCTTGGACATCTGGAGT-3’rev5’-TTCTTTCCAG
CCCTAGCTCA-3’, VEGF for5’-CGAGGGCCTGGAGTG
TGT-3’rev5’-CGCATAATCTGCATGGTGATG-3’, VEGF-
R1 for5’-CGGTCAACAAAGTCGGGAGA-3’rev5’-CAG
TGCACCACAAAGACACG-3’, VE-CADHERIN for5’-
GATCAAGTCAAGCGTGAGTCG-3’ rev5’-AGCCTCT
CAATGGCGAACAC-3’. VCAM1, ICAM, H19 and β-
actin transcript levels were measured by TaqMan Real-
Time PCR using the TaqMan gene expression assay:
Hs00174239_m1, HS 00277001_m1, Hs00262142_g1
and Hs99999903_m1, respectively (Life Technologies,).
Changes in the target mRNA content relative to house-
keeping were determined with the ΔΔct Method.
Endothelial tube formation assay
HUVECs were seeded at 50,000 cells/well in growth
factor-reduced Matrigel-coated 24 well plate and incubated
up to 2 h at 37 °C. Tube formation was examined under
an inverted microscope and photographed at 20× magnifi-
cation. The length of the cables was measured manually
with IMAGE-J software (http://rsbweb.nih.gov/ij/).
FACS analysis
Two hundred thousand (200,000) cells were washed in
PBS and incubated with 0.5 μg ICAM-1-FITC (sc-107,
Santa Cruz). Viable cells were gated by forward and side
scatter, and analyzed on 100,000 acquired events for
each sample. Samples were analyzed on a Partec CyFlow
Space using the Partec FloMax® software.
Adhesion assay
In order to evaluate the ability of CD90+ Huh7 cells and
SkHep cells to adhere to HUVECs, an adhesion assay
was performed, as previously described [26].
ELISA
HUVEC conditioned medium was collected 18 h after
exosome treatment or transfection with pH19 or pEmpty.
VEGF concentrations were quantified using the ELISA kit
(KHG0111, LifeTechnologies), according to manufac-
turer’s protocol.
Array for long non-coding RNA
In order to study lncRNA expressed in the sorted popu-
lation, a LncProfiler lncRNA qPCR array was performed
(System Bioscience) on Huh7, CD90 + Huh7 cells and
their exosomes following manufacturer’s indications.
After amplification, ΔΔct of CD90 +Huh7 was normal-
ized on ΔΔct of Huh7, and data were expressed as fold
induction of the sorted population compared with the
parental cells.
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Statistical analysis
In vitro experiments were repeated three times, giving
reproducible results. Data are presented as mean
values ± standard deviation (SD) of three independent
experiments. Statistical analysis was done using Prism
4 (GraphPad Software Inc., San Diego, CA, USA);
one-way ANOVA (non-parametric) was performed,
followed by Dunnett’s multiple comparison test.
Additional file
Additional file 1: (a) Characterization of isolated exosomes.
Left panel: DSL for exosomes released by SKHep Middle panel: Western
blot forTsg101 and HSC70 in SkHep cells and their relative exosomes.
Right panel: Confocal microscopy analysis on HUVECs treated for 1, 3 and
6 hours with 5 mg/ml of SKHep-derived exosomes. HUVECs were stained
with phalloidin Alexa Fluor (green), nuclear counterstaining was performed
using DAPI (blue), exosomes were labelled with PKH26 (red). (b) Target
analysis. Real time-PCR analysis on HUVECs treated for 18 h with 5 mg/ml
of SkHep-derived exosomes. Normalized for b-actin the DDct were
indicated as fold of induction respect to control (untreated cells).
*p<0.05. (c) Tubulogenesis of HUVECs after exosomes treatment.
Matrigel assay performed on HUVECs cells after 18 hour of 5 mg/ml
SkHep-derived exosomes. Left panel: phase contrast, magnification 20x.
Right panel: quantification of matrigel assay expresses as length of cable
as arbitrary unit **p<0.01. (d) Adhesion assay of SkHep cells on
HUVECs. Left panel: phase contrast, magnification 10X. Right Panel:
quantification of Huh7 or SKHep cells adherent on HUVECs, performed
by counting the number of CD90+adherent cells (violet) per field
***p<0.001. (e) Analysis on H19 expression in exosomes. Real time-PCR
analysis for H19 expression performed on SkHep-derived exosomes respect
to Huh7 derived exosomes. Normalized for b-actin the DDct were indicated
as fold of induction. **p<0.01 (f) Comparison of H19 expression in HUVECs
after exosomes treatment. Real time-PCR analysis for H19 expression on
HUVECs treated for 18 h with 5 mg/ml of SkHep or Huh7 exosomes.
Normalized for b-actin the DDct were indicated as fold of induction respect
to control (untreated cells). (DOCX 855 kb)
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